Arvinas just spent the most consequential quarter in its history turning a science project into a commercial asset, and the equity is still trading like the science project is all there is. On June 5, 2026 the FDA approved VEPPANU (vepdegestrant), the first-ever PROTAC (a proteolysis targeting chimera, meaning a small molecule that binds a target protein on one end and an E3 ubiquitin ligase on the other, hijacking the cell's natural garbage disposal to destroy disease-driving proteins) degrader ever cleared in the United States, for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy. Six days later Arvinas and partner Pfizer closed a global out-license of the molecule to Rigel Pharmaceuticals, pulling in $35.0 million of net cash in the second quarter, retiring Arvinas's remaining performance obligation on the program, and converting the asset into royalty participation plus contingent milestones worth up to $320.0 million in aggregate. The print that landed on August 4, 2026 reflected all of that: $249.7 million of revenue, GAAP net income of $169.4 million, and diluted earnings per share of $2.58, versus a $61.2 million GAAP net loss in the year-ago quarter.
The thesis is that Arvinas is no longer a binary platform bet where the entire equity is priced on whether one Phase 3 readout goes well, it is now a multi-asset clinical developer with one approved degrader earning royalties, four Phase 1 oncology and neurology programs with data catalysts over the next 12 months, and a balance sheet that runs into the second half of 2028 without needing another financing. The market is still pricing this story at a $585.7 million market capitalization against $567.9 million of cash, which means investors are ascribing near-zero option value to ARV-393, ARV-102, ARV-027, ARV-806 and ARV-6723 in aggregate. The mechanism that drives the trade is straightforward: a portfolio of PROTAC degraders that have already produced one FDA approval and four early-stage clinical signals, valued by the public market for less than the cash on the balance sheet.
The single load-bearing risk is execution. The CMO (chief medical officer) departed on July 3, 2026 and a permanent replacement has not yet been named, vepdegestrant's commercial trajectory now belongs to Rigel rather than Arvinas, and three of the four Phase 1 readouts that anchor the next twelve months of catalyst flow are early-stage data points where the historical base rate of clinical failure in oncology is high. The falsifiable clock is the ARV-393 dose-escalation update, the ARV-102 multiple-dose Parkinson's data set already in hand, and the ARV-027 multiple-ascending-dose read in healthy volunteers, each of which either confirms or invalidates the multi-asset thesis inside the next four to six quarters.